CMR in pediatric cardiomyopathy-CMR in pediatric cardiomyopathy

Video Transcription

Video Summary

The conference opened with a welcome to the SCMR Congenital Case Conference and instructions for muted participation and questions via chat or WhatsApp. The first presentation, by Lindsey Griffin, focused on how cardiac MRI can be used to assess pediatric cardiomyopathy and myocarditis. Through several cases, she highlighted the practical use of T2 edema imaging, native T1 mapping, ECV, and late gadolinium enhancement (LGE), emphasizing how these tools can clarify myocardial inflammation and injury, sometimes even without contrast. She also discussed challenges in children, including anesthesia effects, breath-holding limitations, and uncertainty around pediatric normal ranges. Special attention was given to myocarditis in the COVID era, including MIS-C and the current recommendation against routine CMR in asymptomatic COVID patients.<br /><br />The second talk, by Lars Gross-Wartman, addressed CMR for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. He reviewed the limitations of current pediatric risk models and the importance of imaging features such as maximal wall thickness, pattern of hypertrophy, LGE burden, and possibly ischemia-related findings. He emphasized that LGE—especially when extensive—may add prognostic value beyond echo and clinical markers, though pediatric data remain limited. He also touched on myocardial bridging, microvascular ischemia, and the possible future role of T1/ECV mapping.<br /><br />The session ended with a lively Q&A on LGE quantification, pediatric mapping norms, RV insertion-point enhancement, ARVD screening, and MRI under anesthesia.

Keywords

cardiac MRI

pediatric cardiomyopathy

myocarditis

T2 edema imaging

native T1 mapping

extracellular volume

late gadolinium enhancement

hypertrophic cardiomyopathy

sudden cardiac death risk

pediatric CMR